Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Other Non-Current Liabilities (2020 - 2025)

Treace Medical Concepts' Other Non-Current Liabilities history spans 6 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 3043.3% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, up 3043.3%, while the annual FY2025 figure was $3.0 million, 3043.3% up from the prior year.
  • Other Non-Current Liabilities reached $3.0 million in Q4 2025 per TMCI's latest filing, up from $37000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.0 million in Q4 2025 to a low of $25000.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 5 years is $279470.6, with a median of $97000.0 recorded in 2024.
  • The largest YoY upside for Other Non-Current Liabilities was 3043.3% in 2025 against a maximum downside of 76.58% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $173000.0 in 2021, then tumbled by 52.02% to $83000.0 in 2022, then plummeted by 55.42% to $37000.0 in 2023, then surged by 162.16% to $97000.0 in 2024, then skyrocketed by 3043.3% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Other Non-Current Liabilities are $3.0 million (Q4 2025), $37000.0 (Q3 2025), and $154000.0 (Q2 2025).